Our Experiences with Erlotinib in Second and Third Line Treatment Patients with Advanced Stage Iiib/ Iv Non-Small Cell Lung Cancer. (2008). Biomolecules and Biomedicine, 8(4), 386-390. https://doi.org/10.17305/bjbms.2008.2905